22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On March 7, 2019, the U.S. Department of Labor issued a Notice of Proposed Rulemaking (“Proposed Ru...
Read More >
The U.S. Court of Appeals for the 3rd Circuit recently vacated a district court’s order compelling ...
Read More >
As they once said in This is Spinal Tap, there is a fine line between stupid and clever. I can assur...
Read More >
Since 2015, employers and health insurers have been required to report health plan coverage informat...
Read More >
On June 27, 2019, Governor Gavin Newson (D) signed Senate Bill (SB) 83, which, beginning on July 1, ...
Read More >
With the start of the new year, California’s new law prohibiting hair discrimination has taken effe...
Read More >